Schedule 13G ownership disclosure
Taysha Gene Therapies Inc
Common Stock, par value $0.00001 per share · CUSIP: 877619106
Event date: 2025-06-26
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- THE GOLDMAN SACHS GROUP, INC.
Shares: 12,748,968.00 · Class: 5.1%
- GOLDMAN SACHS & CO. LLC
Shares: 12,748,968.00 · Class: 5.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000769993-25-000401
- Form type
- SCHEDULE 13G
- Filer
- GOLDMAN SACHS GROUP INC
- CIK
- CIK 886982
- Filed
- Jul 03, 2025
- Reporting period
- Jun 26, 2025
- Description
- Schedule 13G beneficial ownership